Beijing Sun-Novo Pharmaceutical Research Future Growth
Future criteria checks 6/6
Beijing Sun-Novo Pharmaceutical Research is forecast to grow earnings and revenue by 29.5% and 28.7% per annum respectively. EPS is expected to grow by 29.6% per annum. Return on equity is forecast to be 23.6% in 3 years.
Key information
29.5%
Earnings growth rate
29.6%
EPS growth rate
| Life Sciences earnings growth | 32.9% |
| Revenue growth rate | 28.7% |
| Future return on equity | 23.6% |
| Analyst coverage | Low |
| Last updated | 25 Aug 2024 |
Recent future growth updates
No updates
Recent updates
Investors Still Aren't Entirely Convinced By Beijing Sun-Novo Pharmaceutical Research Co., Ltd.'s (SHSE:688621) Earnings Despite 40% Price Jump
Oct 02
Concerns Surrounding Beijing Sun-Novo Pharmaceutical Research's (SHSE:688621) Performance
Sep 05Market Still Lacking Some Conviction On Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHSE:688621)
Jul 31We Think Beijing Sun-Novo Pharmaceutical Research (SHSE:688621) Can Stay On Top Of Its Debt
May 29Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 2,161 | 440 | N/A | 421 | 1 |
| 12/31/2025 | 1,646 | 372 | N/A | 324 | 1 |
| 12/31/2024 | 1,244 | 277 | N/A | 253 | 1 |
| 9/30/2024 | 1,157 | 221 | 127 | 174 | N/A |
| 6/30/2024 | 1,034 | 215 | 1 | 70 | N/A |
| 3/31/2024 | 952 | 210 | 122 | 182 | N/A |
| 12/31/2023 | 932 | 185 | 20 | 93 | N/A |
| 9/30/2023 | 873 | 199 | 45 | 123 | N/A |
| 6/30/2023 | 813 | 187 | -55 | 24 | N/A |
| 3/31/2023 | 761 | 171 | -83 | 17 | N/A |
| 12/31/2022 | 677 | 156 | 0 | 104 | N/A |
| 9/30/2022 | 648 | 149 | -91 | 51 | N/A |
| 6/30/2022 | 594 | 134 | -55 | 84 | N/A |
| 3/31/2022 | 546 | 119 | -19 | 86 | N/A |
| 12/31/2021 | 494 | 106 | 3 | 88 | N/A |
| 9/30/2021 | 454 | 107 | 23 | 61 | N/A |
| 6/30/2021 | 416 | 91 | 38 | 65 | N/A |
| 3/31/2021 | 369 | 76 | 14 | 51 | N/A |
| 12/31/2020 | 347 | 72 | 36 | 63 | N/A |
| 12/31/2019 | 234 | 47 | 31 | 57 | N/A |
| 12/31/2018 | 135 | 21 | 28 | 44 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 688621's forecast earnings growth (29.5% per year) is above the savings rate (2.8%).
Earnings vs Market: 688621's earnings (29.5% per year) are forecast to grow faster than the CN market (26.2% per year).
High Growth Earnings: 688621's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 688621's revenue (28.7% per year) is forecast to grow faster than the CN market (13.8% per year).
High Growth Revenue: 688621's revenue (28.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 688621's Return on Equity is forecast to be high in 3 years time (23.6%)